Genmab Announced Earlier Today That Appeal Arbitrator In Its Second Arbitration Arising Under Its License Agreement With Janssen For Daratumumab Has Denied Genmab’s Appeal
Genmab A/S (NASDAQ:GMAB) announced today that the appeal arbitrator in its second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab has denied Genmab’s appeal. As